Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
randomization-Fundacion Investigacion Interhospitalaria Cardiovascular-type 2 diabetes mellitus-stable ischemic heart disease
- Development stage
- Unknown
- Lead developer
- Fundación Interhospitalaria para la Investigación Cardiovascular
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a clinical study context, specifically the Phase 4 PREDICT trial (PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor), sponsored by the Fundacion Investigacion Interhospitalaria Cardiovascular. The study compares the effects of two P2Y12 inhibitors, **Ticagrelor** and **Clopidogrel**, on coronary microcirculation (measured by Index of Microcirculatory Resistance and Coronary Flow Reserve) in patients with type 2 diabetes mellitus or pre-diabetes undergoing percutaneous coronary intervention (PCI) for stable ischemic heart disease. Ticagrelor is a reversible, direct-acting P2Y12 receptor antagonist, while Clopidogrel is an irreversible P2Y12 antagonist prodrug. The trial aims to determine if Ticagrelor offers superior protection of the microvascular bed during PCI compared to Clopidogrel in this high-risk population.
- Brand names
- BrilintaPlavix
- Other names
- TicagrelorClopidogrelPREDICT trial intervention
02
Targets
P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on randomization-Fundacion Investigacion Interhospitalaria Cardiovascular-type 2 diabetes mellitus-stable ischemic heart disease.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on randomization-Fundacion Investigacion Interhospitalaria Cardiovascular-type 2 diabetes mellitus-stable ischemic heart disease.